But biotechnology companies, and their current valuations, are heavily reliant on prices staying high. If more sensible pricing takes effect, it could burst the bubble and bring those investments crashing down.
Read Full Article »But biotechnology companies, and their current valuations, are heavily reliant on prices staying high. If more sensible pricing takes effect, it could burst the bubble and bring those investments crashing down.
Read Full Article »